

Cover Story
Guest Editorial
The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Early endpoints are a balance of risk and benefit













